Effects of PEP-1-FK506BP on cyst formation in polycystic kidney disease

키워드

참고문헌 (53)

1. Wilson PD, "Cystic disease of the kidney", Annu Rev Patho, 2, pp.341~368 (2007)
2. Pei Y, "Diagnosis and screening of autosomal dominant polycystic kidney disease", Adv Chronic Kidney Dis, 17, pp.140~152 (2010)
3. Harris PC, "Polycystic kidney disease", Annu Rev Med, 60, pp.321~337 (2009)
4. Ye M, "Cyst fluid from human autosomal dominant polycystic kidneys promotes cyst formation and expansion by renal epithelial cells in vitro", J Am Soc Nephrol, 3, pp.984~994 (1992)
5. Yoder BK, "Molecular pathogenesis of autosomal dominant polycystic kidney disease", Expert Rev Mol Med, 8, pp.1~22 (2006)
6. Al-Bhalal L, "Molecular basis of autosomal recessive polycystic kidney disease (ARPKD)", Adv Anat Patho, 15, pp.54~58 (2008)
7. Gardner KD Jr, "Cytokines in fluids from polycystic kidneys", Kidney Int, 39, pp.718~724 (1991)
8. 박은영, "Polycystic kidney disease and therapeutic approaches", BMB Reports, 44(6), pp.359~368 (2011), 생화학분자생물학회
9. Harada H, "Expression of matrix metallo proteinase in the fluids of renal cystic lesions", J Urol, 168, pp.19~22 (2002)
10. Liu B, "Increasing extracellular matrix collagen level and MMP activity induces cyst development in polycystic kidney disease", BMC Nephrol, 13, pp.109~ (2012)
11. Candiano G, "Extracellular matrix formation by epithelial cells from human polycystic kidney cysts in culture", Virchows Arch B Cell Pathol Incl Mol Pathol, 63, pp.1~9 (1992)
12. Lee EL, "Blockage of interleukin-8 receptor signaling inhibits cyst development in vitro, via suppression of cell proliferation in autosomal polycystic kidney disease", Nephrol, 19, pp.471~478 (2014)
13. Canaud G, "Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level?", Am J Transplant, 10, pp.1701~1706 (2010)
14. Zafar I, "Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease", Kidney Int, 78, pp.754~761 (2010)
15. Wahl PR, "Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease", Nephro, 12, pp.357~363 (2007)
16. Ibraghimov-Beskrovnaya O, "mTOR signaling in polycystic kidney disease", Trends Mol Med, 17, pp.625~633 (2011)
17. Fukuda R, "Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells", J Biol Chem, 277, pp.38205~38211 (2002)
18. Zhong H, "Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor", phosphatidylinositol 3-kinase, AKT, pp.FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics, Cancer Res[DOI]
19. Bae WY, "Cinnamic aldehyde suppresses hypoxia-induced angiogenesis via inhibition of hypoxia-inducible factor-1alpha expression during tumor progression", Biochem Pharmacol, 98, pp.41~50 (2015)
20. Mi C, "Imperatori suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1 via the mTOR", p70S6K, J Ethnopharmacol, pp.2017, 203[DOI]
21. Kang CB, "FKBP family proteins: immunophilins with versatile biological functions", Neurosignals, 16, pp.318~325 (2008)
22. Harrar Y, "FKBPs: at the crossroads of folding and transduction", Trends Plant Sci, 6, pp.426~431 (2001)
23. Pong K, "Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases", Curr Drug Targets CNS Neurol Disord, 2, pp.349~356 (2003)
24. Lopez-Ilasaca M, "Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor", J Biol Chem, 273, pp.9430~9434 (1998)
25. Costantini LC, "Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson’s disease", Eur J Neurosci, 13, pp.1085~1092 (2001)
26. Guo X, "Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons", Eur J Neurosci, 13, pp.1683~1693 (2001)
27. Ross DT, "The small molecule FKBP ligand GPI 1046 induces partial striatal re-innervation after intranigral 6-hydroxydopamine lesion in rats", Neurosci Lett, 297, pp.113~116 (2001)
28. Christner C, "FKBP ligands as novel therapeutics for neurological disorders", Mini Rev Med Chem, 1, pp.377~397 (2001)
29. Avramut M, "Immunophilins and their ligands: Insights into survival and growth of human neurons", Physiol Behav, 77, pp.463~468 (2002)
30. Dunlop EA, "Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms", Cell Signal, 21, pp.827~835 (2009)
31. Garcia JA, "Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies", Mol Cancer Ther, 7, pp.1347~1354 (2008)
32. Long C, "FK506 binding protein 12", 12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure, 2007, pp.49, 569~576
33. Raagel H, "Peptide-mediated protein delivery-which pathways are penetrable?", Biochim Biophy Acta, 1798, pp.2240~2248 (2010)
34. Liu Y, "Intravenous PEP-1- GDNF is protective after focal cerebral ischemia in rats", Neurosci Lett, 617, pp.150~155 (2016)
35. Kim SY, "Transduced PEP-1-K506BP ameliorates atopic dermatitis in NC", Nga mice, 2011, pp.131, 1477~1485
36. 김대원, "PEP-1-FK506BP inhibits alkali burn-induced corneal inflammation on the rat model of corneal alkali injury", BMB Reports, 48(11), pp.618~623 (2015), 생화학분자생물학회
37. Liu Y, "Intravenous PEP-1- GDNF is protective after focal cerebral ischemia in rats", Neurosci Lett, 617, pp.150~155 (2016)
38. Tan LG, "PEP-1-SOD1 fusion proteins block cardiac myofibroblast activation and angiotensin II-induced collagen production", BMC Cardiovasc Disord, 15, pp.116~ (2015)
39. 황현숙, "PEP-1-FK506BP12 inhibits matrix metalloproteinase expression in human articular chondrocytes and in a mouse carrageenan-induced arthritis model", BMB Reports, 48(7), pp.407~412 (2015), 생화학분자생물학회
40. Laplante M, "mTOR signaling in growth control and disease", Cell, 149, pp.274~293 (2012)
41. Novalic Z, "Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease", J Am Soc Nephrol, 23, pp.842~853 (2012)
42. Serra AL, "Sirolimus and kidney growth in autosomal dominant polycystic kidney disease", N Engl J Med, 363, pp.820~829 (2010)
43. Walz G, "Everolimus in patients with autosomal dominant polycystic kidney disease", N Engl J Med, 363, pp.830~840 (2010)
44. Shillingford JM, "Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1", J Am Soc Nephrol, 21, pp.489~497 (2010)
45. Foster DA, "Targeting mTOR with rapamycin: one dose does not fit all", Cell Cycle, 8, pp.1026~1029 (2009)
46. Chang ES, "Restoring multidrug resistance-associated protein 3 attenuates cell proliferation in the polycystic kidney", Am J Physiol Renal Physiol, 308, pp.F1004~F1011 (2015)
47. Okada H, "Progressive renal fibrosis in murine polycystic kidney disease: an immunohistochemical observation", Kidney Int, 58, pp.587~597 (2000)
48. Ramasubbu K, "Increased epithelial cell proliferation and abnormal extracellular matrix in rat polycystic kidney disease", J Am Soc Nephrol, 9, pp.937~945 (1998)
49. Rankin CA, "Matrix metalloproteinase-2 in a murine model of infantile-type polycystic kidney disease", J Am Soc Nephrol, 10, pp.210~217 (1999)
50. Watnick T, "mTOR inhibitor in polycystic kidney disease", N Egn J Med, 363, pp.879~881 (2010)
51. Bradford MA, "Rapid and sensitive method for the quantitation of microgram quantities utilizing the principle of protein-dye binding", Anal Biochem, 72, pp.248~254 (1976)
52. 조효상, "Transduced Tat-DJ-1 protein inhibits cytokines-induced pancreatic RINm5F cell death", BMB Reports, 49(5), pp.297~302 (2016), 생화학분자생물학회
53. 조효상, "Protective effects of Tat-NQO1 against oxidative stress-induced HT-22 cell damage, and ischemic injury in animals", BMB Reports, 49(11), pp.617~622 (2016), 생화학분자생물학회

관련 논문AI추천